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Abstract
Background: Numerous studies have been conducted in many countries to identify the factors associated with
readmission of patients with heart failure (HF). However, there have been no such studies utilizing a large-scale
administrative database in Japan. This study aimed to establish the factors associated with 30-day readmission of
patients with HF using a Japanese nationwide administrative database.
Methods: Data of the index admissions of 68,257 patients discharged from 1057 participating hospitals between
April 1, 2012 and March 31, 2013 were analyzed. Patients were divided into the 30-day readmission group and no
readmission group according to whether unplanned HF readmission occurred within 30 days after discharge. Study
variables included age, sex, New York Heart Association functional class (NYHA) at admission, Charlson Comorbidity
Index (CCI), length of stay in hospital (LOS), body mass index (BMI) at admission, hospital volume reflected by the
number of cases hospitalized with HF, and medical treatment at discharge.
Results: The 30-day readmission and no readmission groups included 4479 and 63,778 patients, respectively. The
independent factors associated with the increase in 30-day readmission were older age, higher NYHA, higher CCI,
and use of the following drugs at discharge: beta blockers, loop diuretics, thiazide, and nitrates. In contrast, the
independent factors associated with the decrease in 30-day readmission were longer LOS, higher BMI, and the use
of angiotensin converting enzyme inhibitors (ACEs) or angiotensin II receptor blockers (ARBs), calcium channel
blockers, and spironolactone.
Conclusions: The results suggest that, especially during the first few weeks after discharge, careful management of HF
outpatients with advanced age, high disease severity, multiple comorbidities, or taking beta blockers, loop diuretics,
thiazide, and nitrates at discharge may be crucial for reducing the 30-day readmission rate.
Keywords: Heart failure, 30-day readmission, Japanese administrative database, The Diagnosis Procedure Combination
(DPC) database
Background
Heart failure (HF) is a common syndrome and a frequent
cause of hospital admission. About 26 million adults
worldwide are living with HF, making it a global pandemic
[1]. Approximately 5 million patients with HF reside in the
United States, and 550,000 individuals are diagnosed for
the first time every year [2]. According to the European
Society of Cardiology, the prevalence of HF is 2–3 %, and
there are at least 15 million patients with this disease in
the 51 European countries [3]. Despite the scarcity of data,
the prevalence of HF in Japan has been estimated to be ap-
proximately 1–2 %, and it is rapidly increasing [4, 5]. The
causes of this trend include, among others, the increase of
elderly population, higher survival rate after acute myocar-
dial infarction, and improvements in the treatment of HF
leading to better survival, such as angiotensin converting
enzyme inhibitors (ACEs), angiotensin II receptor blockers
(ARBs), beta blockers, aldosterone antagonists, and elec-
trical devices [6].* Correspondence: kfushimi.hci@tmd.ac.jp1Department of Health Policy and Informatics, Tokyo Medical and Dental
University, Graduate School of Medicine, Tokyo, Japan
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The increase in the number of patients with HF led to
more frequent readmissions of such individuals. Thus, re-
cent studies reported 30-day readmission rates of approxi-
mately 25 % in the United States [7–10]. Since reduction
in readmission rates might simultaneously lower the asso-
ciated costs and improve the quality of care, public and
private payers have progressively targeted readmissions as
a focus of pay-for-performance initiatives [7, 11]. In ac-
cordance with this, basic research and hospital-driven
efforts have been focused on the prediction of which pa-
tients with HF are likely to be readmitted and the design
of interventions to prevent readmissions.
In worldwide numerous studies, many predictors asso-
ciated with readmission of patients with HF have been
recognized and racial/ethnic differences have been indi-
cated [12, 13]. Although several registries and observa-
tional studies for patients with HF, including the Acute
Decompensated Heart Failure Syndromes (ATTEND)
registry [14], the Japanese Cardiac Registry of Heart Failure
in Cardiology (JCARE-CARD) [15], and the Chronic Heart
Failure Analysis and Registry in the Tohoku District 2
(CHART-2) Study [16], have been performed in Japan,
large-scale administrative databases have not been utilized
in such investigations. The aim of this study was to identify
the factors associated with 30-day readmission of patients
with HF in Japan, using a Japanese nationwide administra-
tive database termed the Diagnosis Procedure Combin-
ation (DPC) database [17, 18].
Methods
Data source
The present study used the DPC database from patients
discharged between April 1, 2012 and March 31, 2013. The
database contains both digitized discharge summaries and
claims data from 1057 participating hospitals, covering ap-
proximately 48 % of all hospitalizations to acute care hospi-
tals in Japan. The database includes patient information on
demographics, primary diagnosis, comorbidities present on
admission, complications occurring during hospitalization,
medical procedures, medications, and materials. Patients
with HF as the principal disease or the disease associated
with the highest medical costs were identified based on the
following codes of the 10th revision of the International
Statistical Classification of Diseases (ICD10): I50.0, I50.1,
I50.9, I09.9, I11.0, and E05.9. Figure 1 shows the patient
selection process. This study included patients older than
15 years at the time of hospital admission. The index ad-
missions occurred in March 2013 were excluded because
Fig. 1 Selection of patients with heart failure from the Diagnostic Procedure Combination (DPC) database. aMissing data included New York
Heart Association functional class (NYHA), body mass index (BMI), and medical treatment at discharge
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we lacked the complete 30 days of follow-up. Cases with
planned readmission, in-hospital death, missing data or
cardiothoracic surgery were excluded. The study was ap-
proved by the Tokyo Medical and Dental University ethics
committee.
Study design
Thirty-day readmission was defined as unplanned HF re-
admission within 30 days after discharge (30-day readmis-
sion group). The 30-day readmission group was compared
to the no readmission group, which was composed of the
patients who did not require rehospitalization within the
same period. If a patient was hospitalized multiple times
with HF exacerbation during the study period, only the
index admission of the shortest time up to rehospitaliza-
tion was extracted to maintain the independence of obser-
vations. Patients who were readmitted to other hospitals
were not included in the 30-day readmission group in this
study, because the patient registration numbers were
different for every hospital. Patients who died before re-
admission were also not included in the 30-day readmis-
sion group, because outpatient data after discharge from
the index admission could not be surveyed.
Variables
Variables used in the present study included age, sex,
New York Heart Association functional class (NYHA) at
admission, Charlson Comorbidity Index (CCI) [19, 20],
length of stay in hospital (LOS), body mass index (BMI)
at admission, hospital volume reflected by the number
of cases hospitalized with HF, and medical treatment at
discharge (ACEs or ARBs, beta blockers, calcium channel
blockers, digitalis, loop diuretics, thiazide, spironolactone,
and nitrates). Patients were categorized into three age
groups: < 65, 65–74, and ≥ 75 years old; four CCI groups:
≤ 1, 2, 3, and ≥ 4; and three hospital volume groups: ≤ 68,
69–150, and ≥ 151 cases.
Statistical analysis
Summary statistics of categorical patient characteristics and
the details of the prescribed medicines at discharge were
described as numbers and percentages, and continuous var-
iables were described as medians and interquartile ranges
(IQRs). Bi-variable analyses were employed to compare the
30-day readmission and no readmission groups for each
candidate predictor using the chi-square test for categorical
variables and the Wilcoxon rank-sum test for continuous
variables. Multivariable logistic regression analysis after
controlling simultaneously for each variable was performed
to determine the factors associated with 30-day readmission
of patients with HF. In multivariable regression analysis, an
important assumption is that explanatory variables are
independent of each other. Therefore, we used variance in-
flation factors (VIFs) to test for multicollinearity among the
predictor variables. A VIF exceeding 10 was regarded as in-
dicating serious multicollinearity, and a value greater than
4.0 was considered a cause for concern [21]. P-values,
adjusted odds ratios (ORs), and corresponding two-sided
95 % confidence intervals (CIs) were obtained for the pre-
dictors. The statistical analyses were performed using
release 11 of the JMP software package (SAS Institute
Inc., Cary, NC, USA). P-values < 0.05 were considered
to represent statistical significance.
Results
This study included the index admissions of 68,257 patients
who met the inclusion and exclusion criteria. Of these pa-
tients, 4479 and 63,778 were categorized into the 30-day
readmission and no readmission groups, respectively.
The demographic characteristics are shown in Table 1.
In unadjusted comparisons, the patients in the 30-day
readmission group were significantly older (P < 0.0001),
had higher NYHA at admission (P < 0.0001), higher CCI
(P < 0.0001), and lower BMI (P < 0.0001) than the patients
in the no readmission group. Table 2 summarizes the
medications prescribed at discharge to the subjects. In un-
adjusted comparisons, significantly fewer patients in the
30-day readmission group were taking ACEs or ARBs
(P < 0.0001), calcium channel blockers (P < 0.0001), and
spironolactone (P < 0.0001) than the subjects in the no re-
admission group, whereas more patients were taking beta
blockers (P = 0.0001), loop diuretics (P < 0.0001), thiazide
(P = 0.0001), and nitrates (P < 0.0001).
The VIFs for the predictor variables in this study were
all < 4.0, indicating the absence of multicollinearity. The
multivariable analysis revealed the following demographic
factors and prescribed medications associated with in-
creased 30-day readmission of patients with HF: older age,
higher NYHA, and higher CCI, and use of beta blockers,
loop diuretics, thiazide, and nitrates. In contrast, the fac-
tors associated with reduced 30-day readmission of
patients with HF included longer LOS, higher BMI, and
use of ACEs or ARBs, calcium channel blockers, and spir-
onolactone (Table 3).
Discussion
The present study is the largest multicenter observational
study using an administrative database for patients with
HF in Japan. First, we identified several factors associated
with the increase in 30-day readmission of patients with
HF. In agreement with previous reports [22–24], these
factors included older age, higher NYHA, and higher CCI.
Furthermore, other factors were the use of beta blockers,
loop diuretics, thiazide, and nitrates. Beta blocker therapy
has contributed to reduction in mortality and long-term
hospitalization in patients with systolic HF and has been
used in most patients with HF [25–29]. However, initi-
ation and up-titration of beta blockers may result in
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short-term hospital admission for worsening HF because
of the negative inotropic and chronotropic effects. A pre-
vious study demonstrated that high starting dose of beta
blockers was associated with increased readmission risk
for patients with HF [30]. Although the lack of outpatient
data prevented analysis of the dose of beta blockers, blood
pressure, or cardiac function in the current study, we as-
sumed that the dose of beta blockers might influence the
increase in 30-day readmission. Loop diuretics remain the
mainstay of decongestive therapy in acute HF and appear
to benefit patients with acute HF when included in initial
Table 2 The summary of the medications prescribed at
discharge
Readmission No readmission P-value
Number of patients 4479 63778
ACEs or ARBs [n (%)] 2216 (49.5) 36076 (56.6) <0.0001
Beta blockers [n (%)] 1883 (42.0) 24947 (39.1) 0.0001
Ca channel blockers [n (%)] 1074 (24.0) 17457 (27.4) <0.0001
Digitalis [n (%)] 484 (10.8) 7383 (11.6) 0.119
Loop diuretics [n (%)] 3631 (81.1) 49703 (77.9) <0.0001
Thiazide [n (%)] 375 (8.4) 4379 (6.9) 0.0001
Spironolactone [n (%)] 1383 (30.9) 22512 (35.3) <0.0001
Nitrates [n (%)] 940 (21.0) 9850 (15.4) <0.0001
The P-values were calculated with the chi-square test
ACEs angiotensin converting enzyme inhibitors; ARBs angiotensin II receptor
blockers; Ca channel blockers calcium channel blockers
Table 3 Adjusted OR and 95 % CI for the factors associated
with 30-day readmission
Adjusted OR 95 % CI P-value
Age <65 reference
65–74 1.267 1.127–1.425 <0.0001
≥75 1.330 1.199–1.475 <0.0001
Male 0.982 0.922–1.046 0.568
NYHA I reference
II 1.354 1.179–1.556 <0.0001
III 1.548 1.351–1.774 <0.0001
IV 1.627 1.416–1.869 <0.0001
CCI 1.087 1.065–1.108 <0.0001
LOS 0.997 0.995–0.998 <0.0001
BMI 0.972 0.964–0.979 <0.0001
Hospital volume 1.000 1.000–1.000 0.932
ACEs or ARBs 0.749 0.703–0.798 <0.0001
Beta blockers 1.225 1.149–1.306 <0.0001
Ca channel blockers 0.834 0.776–0.896 <0.0001
Digitalis 0.935 0.847–1.033 0.185
Loop diuretics 1.286 1.187–1.394 <0.0001
Thiazide 1.280 1.145–1.431 <0.0001
Spironolactone 0.795 0.743–0.851 <0.0001
Nitrates 1.405 1.302–1.516 <0.0001
OR odds ratio; 95 % CI 95 % confidence interval; NYHA New York Heart
Association functional class; CCI Charlson Comorbidity Index; LOS length of
stay in hospital; BMI body mass index; Hospital volume number of cases
hospitalized with heart failure; ACEs angiotensin converting enzyme inhibitors;
ARBs angiotensin II receptor blockers; Ca channel blockers calcium
channel blockers
Table 1 The basic characteristics of the study patients
Readmission No readmission P-value





<65 487 (10.9) 9898 (15.5)
65–74 802 (17.9) 11598 (18.2)
≥75 3190 (71.2) 42282 (66.3)
Male [n (%)] 2351 (52.5) 33981 (53.3) 0.305a
NYHA [n (%)] <0.0001a
I 254 (5.7) 5411 (8.5)
II 1235 (27.6) 19168 (30.1)
III 1652 (36.9) 22164 (34.8)
IV 1338 (29.9) 17035 (26.7)




≤1 1181 (26.4) 19906 (31.2)
2 1187 (26.5) 17992 (28.2)
3 1025 (22.9) 13543 (21.2)











≤68 1079 (24.1) 16116 (25.3)
69–150 2356 (52.6) 31904 (50.0)
≥151 1044 (23.3) 15758 (24.7)
IQR interquartile range; NYHA New York Heart Association functional class; LOS
length of stay in hospital; BMI body mass index; Hospital volume number of
cases hospitalized with heart failure
aCalculated using the chi-square test; the remaining P-values were calculated
with the Wilcoxon rank-sum test
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therapies [6]. Our result is in line with the data from a
published report indicating that outpatient loop diuretics
therapy was associated with increased 60-day readmission
of patients with HF [31]. Thiazide is useful for reducing
volume load in patients with diastolic dysfunction [32].
However, thiazide is usually utilized in combination with
loop diuretics, ACEs, or ARBs, and the use of thiazide
monotherapy is uncommon in patients with HF [33, 34].
Therefore, we have not been able to identify published
reports of whether thiazide is associated with increased
readmission of patients with HF. Nitrates have been used
as vasodilators in the early stages of acute HF for many
years [3, 35]. Although nitrate therapy may reduce the
symptoms of dyspnea at night and during exercise in pa-
tients with HF [36], it has never been evaluated during the
first few weeks after discharge in a prospective randomized
study. Our results suggest that, especially during the first
few weeks after discharge, careful management of HF out-
patients with advanced age, high disease severity, many co-
morbidities, or the use of the above drugs at discharge may
be an important factor for reducing 30-day readmission.
Second, the present study identified longer LOS, higher
BMI, and the use of ACEs or ARBs, calcium channel
blockers, and spironolactone as the factors associated with
reduced 30-day readmission of patients with HF. Contrary
to our finding, longer LOS has been shown to be a pre-
dictor of future readmission in Medicare analyses within
the United States cohorts [12, 37]. According to a previous
report, the average LOS for all hospital admissions in
Japan is two to three times longer than that in the United
States [38], and this difference is likely a convincing factor
leading to this discrepancy. The difference in the average
LOS in Japan and the United States is likely related to a
number of factors, such as the social context, the universal
health coverage, and the demographic cohorts. Further-
more, Japanese hospitals generally provide rehabilitation
and nursing care in addition to acute medical care, which
may also contribute to the longer LOS. We found that
higher BMI was associated with reduced 30-day readmis-
sion of patients with HF, which seems to confirm the ex-
istence of the so-called “obesity paradox” in patients with
HF discovered in previous studies [39, 40]. In contrast, a
single study from Japan showed that BMI levels were not
associated with rehospitalization for worsening HF [41],
necessitating further research. The use of ACEs or ARBs,
calcium channel blockers, and spironolactone was shown
to prevent hospitalizations for HF in previous reports
[42–49], and our results suggest that these factors might
contribute to the decrease in 30-day readmission.
Study limitations
Some limitations of this study should be noted. First, pa-
tients who were readmitted to other hospitals were not in-
cluded in the 30-day readmission group in this study,
because the patient registration numbers were different
for every hospital. This point is very important and would
underestimate the readmission rate. Second, our data did
not include important information on the clinical status,
laboratory data, and cardiac function at admission (such
as blood pressure, serum creatinine levels, and ejection
fraction). Consequently, the clinical characteristics of the
patients hospitalized with worsening HF have not been
well described. Third, because we could not combine the
DPC database with outpatient claims data, outpatient data
after discharge from the index admission were not sur-
veyed. Therefore, patients who died before readmission
were not included in the 30-day readmission group in this
study. These points may represent disadvantages of the
current study when compared with other registries and
observational studies, and they may have influenced the
results of our analyses.
Conclusions
The present study is the largest Japanese multicenter ob-
servational study using an administrative database of
patients with HF. According to the results of multivariable
analysis, the factors associated with the increase in 30-day
readmission of patients with HF were older age, higher
NYHA, and higher CCI, as well as the use of beta blockers,
loop diuretics, thiazide, and nitrates. In contrast, the factors
associated with the decrease in 30-day readmission were
longer LOS, higher BMI, and the use of ACEs or ARBs,
calcium channel blockers, and spironolactone. Therefore,
careful management, especially during the first few weeks
after discharge, of outpatients with HF who have advanced
age, high disease severity, many comorbidities, or take beta
blockers, loop diuretics, thiazide, and nitrates at discharge
may be crucial for reducing the 30-day readmission rate.
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